希罗达用于晚期宫颈癌维持治疗的报道

卡培他滨维持性口服治疗宫颈癌的临床研究     


【英文篇名】 Clinical study of capecitabine in the maintenance treatment of patients with cervical cancer
【作者】 谭洁媚; 李明毅; 梁颖;
【英文作者】 TAN Jie-mei *; LI Ming-yi; LIANG Ying. * The Affiliated Jiangmen Hospital of Sun yat-sen University; Guangdong 529000; China;
【机构】 广东省江门市中心医院; 中山大学附属江门医院; 中山大学附属肿瘤医院;
【关键词】 卡培他滨; 宫颈癌; 维持治疗;
【英文关键词】 Capecitabine; Cervical Cancer; Maintenance treatment;
【中文刊名】 临床合理用药杂志, 2013年 14期
【英文刊名】 Chinese Journal of Clinical Rational Drug Use
【中英文摘要】 目的探讨卡培他滨维持性口服治疗宫颈癌的近期疗效及不良反应。方法将96例宫颈癌患者随机分为高剂量维持组、低剂量维持组及对照组各32例。对照组单纯予以紫杉醇联合顺铂化疗方案治疗。在对照组治疗基础上,高剂量维持组应用卡培他滨1000mg/m2进行维持性治疗,低剂量维持组应用卡培他滨500mg/m2进行维持性治疗。比较3组的临床近期疗效及不良反应。结果高剂量维持组、低剂量维持组及对照组有效率分别为50.0%、46.9%、46.9%,3组间比较差异无统计学意义(P>0.05)。在1年生存率、中位进展时间和中位生存时间方面,均为低剂量维持组>高剂量维持组>对照组(P<0.05)。且低剂量维持组不良反应发生情况优于高剂量维持组,差异有统计学意义(P<0.05)。结论卡培他滨维持性口服治疗晚期宫颈癌疗效佳,且低剂量药物引起的不良反应明显较高剂量轻,临床应用方便,利于长期使用。


另外一个是外国的病例
　卡培他滨维持治疗：晚期宫颈癌预料之外的缓解和耐受性良好的方案——一个病例报告

　　Maintenance therapy with capecitabine: unexpected remission of advanced cervical cancer and well tolerated regimen. A case report

　　F. Amouzegar Hashemi1, N. Behtash2, S. Goodarzi2, S. Akhavan3

　　1Department of Radiation Oncology, Tehran University of Medical Science, Cancer Institut, 2Department of Gynecology Oncology, 3Tehran University of Medical Science, Tehran, Iran

　　Cervical cancer continues to be a significant health burden worldwide. Globally, the majority of cancers are locally advanced at diagnosis, hence, radiation remains the most frequently used therapeutical modality, however the prognosis of advanced stages is extremely poor and cure is rare. We present a case of persistent stage IIIb cervical cancer in which the patient remains disease-free about two years after beginning treatment with capacitabine(xeloda) 500mg twice daily every 2 weeks monthly. This is a well tolerated regimen without impairment in quality of life. In rare cases an unexpected complete clinical remission and long-term survival without evidence of disease may be achieved in patients with advanced, recurrent or metastatic cervical cancer treated with multimodal therapy.

这个方案是希罗达500mg，每天两次，每个月吃两个星期，该名IIIB期病人维持了两年无进展。